Cost-Effectiveness of Ibrutinib and Rituximab for the Relapsed or Refractory Chronic Lymphocytic Leukemia in China
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.198
https://www.valueinhealthjournal.com/article/S1098-3015(18)30498-4/fulltext
Section Title :
Section Order :
1047
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30498-4&doi=10.1016/j.jval.2018.04.198